Richard S. Lindahl net worth and biography

Richard Lindahl Biography and Net Worth

Mr. Lindahl was appointed as executive vice president, chief financial officer and treasurer in March 2018. Mr. Lindahl has more than two decades of financial leadership experience. From May 2009 to April 2017, he was chief financial officer of CEB Inc., a best practice insight and technology company. From 2006 to 2008, he served as senior vice president and treasurer of Sprint Nextel Corporation and from 2005 to 2006, he served as vice president and treasurer of Sprint Nextel. From 1997 until 2005, Mr. Lindahl served in various positions at Nextel Communications, Inc., including as treasurer and in financial planning and analysis roles. Prior to joining Nextel, from 1995 until 1997, Mr. Lindahl held the position of vice president, finance at Pocket Communications, Inc. Before 1995, Mr. Lindahl held various positions at MCI Communications Corp., Deloitte & Touche LLP, and Casher Associates, Inc. Mr. Lindahl earned a B.A. in computer science from Dartmouth College and an M.B.A. from the Darden School at the University of Virginia.

How old is Richard S. Lindahl?: Mr. Lindahl is currently 60 years old. There are 4 older executives and no younger executives at Emergent BioSolutions. The oldest executive at Emergent BioSolutions is Mr. Joseph C. Papa Jr., CEO, President & Director, who is 68 years old. Learn More on Richard S. Lindahl's age.
How do I contact Richard S. Lindahl?: The corporate mailing address for Mr. Lindahl and other Emergent BioSolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent BioSolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Richard S. Lindahl's contact information.
Has Richard S. Lindahl been buying or selling shares of Emergent BioSolutions?: Richard S. Lindahl has not been actively trading shares of Emergent BioSolutions during the last ninety days. Most recently, on Monday, November 15th, Richard S. Lindahl bought 3,000 shares of Emergent BioSolutions stock. The stock was acquired at an average cost of $37.46 per share, with a total value of $112,380.00. Learn More on Richard S. Lindahl's trading history.
Are insiders buying or selling shares of Emergent BioSolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 3,530 shares worth more than $29,526.50. The most recent insider tranaction occured on June, 2nd when Director Kathryn C Zoon sold 1,830 shares worth more than $15,280.50. Insiders at Emergent BioSolutions own 1.2% of the company. Learn More about insider trades at Emergent BioSolutions.
Information on this page was last updated on 6/2/2023.

Richard S. Lindahl Insider Trading History at Emergent BioSolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/15/2021	Buy	3,000	$37.46	$112,380.00

Richard S. Lindahl Buying and Selling Activity at Emergent BioSolutions

Emergent BioSolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $1.95

$1.93

$2.01

50 Day Range

MA: $2.44

$1.53

$3.41

2 Week Range

Now: $1.95

$1.42

$10.88

Volume

485,612 shs

Average Volume

2,602,784 shs

Market Capitalization

$102.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.